Skip to main
AMGN
AMGN logo

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 15 analyst ratings
Hold
Strong Buy 13%
Buy 27%
Hold 53%
Sell 7%
Strong Sell 0%

Bulls say

Amgen exhibits a positive financial outlook driven by its robust pipeline and significant growth in research and development, with management forecasting an increase exceeding 20% in R&D expenditure for 2025 compared to 2024. The company's strong sales momentum is evidenced by Uplizna's approximately 58% growth in June 2025 compared to the previous quarter and a 40% increase relative to June 2024. These factors, along with ongoing advancements in its therapeutic offerings, support a compelling case for potential multiple expansion, as reflected in an expected EV/2026E EBITDA of around 13x.

Bears say

Amgen's financial outlook appears negative due to increasing competition in the biotechnology sector, particularly with the introduction of biosimilars and alternative treatments for key therapies, which may erode market share and pricing power. Additionally, the company's reliance on a limited number of flagship drugs, some of which are facing patent expirations and declining sales, raises concerns about sustained revenue growth. Furthermore, the significant costs associated with recent acquisitions and the ongoing need for extensive research and development investments may place pressure on profitability in the near term.

Amgen (AMGN) has been analyzed by 15 analysts, with a consensus rating of Hold. 13% of analysts recommend a Strong Buy, 27% recommend Buy, 53% suggest Holding, 7% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 15 analysts, Amgen (AMGN) has a Hold consensus rating as of Oct 14, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $322.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $322.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.